Africa CDC Call for Applications: Data and Safety Monitoring Board (DSMB) Training Course
Africa CDC calls for application for the course on Data and Safety Monitoring Board (DSMB) Training Course.
Start Date: 23rd of June, 2025.
Duration: 8 weeks.
Venue: Hybrid
Language: English.
The training aims to expand the pool of qualified data safety monitoring board (DSMB) members by upscaling the availability of trained experts in safety monitoring. The program works to support the ethical oversight of vaccine clinical trials in Africa and improve global preparedness for emerging health threats. The program is an 8-week training that includes self-paced learning and live virtual sessions facilitated by leading experts in vaccine safety and clinical trial monitoring. Upon successful completion, participants can then join the DSMB global pool, where they may be considered for future clinical trial oversight roles.
What the Training Covers:
The eight-week-long intensive training course will employ a modular format, combining recorded lectures with live virtual sessions, an approach that ensures flexibility while maintaining interactive learning environment. Expert trainers and subject matter specialists drawn from across the world will facilitate sessions, leveraging their real-world experience to provide high-quality instruction.
- Introduction to Clinical Trials & DSMB
- Vaccine Clinical Trials & Safety Monitoring
- DSMB Roles & Decision-Making
- Regulatory & Ethical Considerations
- Safety Monitoring & Risk Assessment
- Statistical Methods for DSMB
- DSMB Meetings & Case Discussions
- Practical Applications, quizzes and final assessment
- Stronger Regulatory and Ethical Compliance.
- Better equipped to align clinical trial practices with Good Clinical Practice (GCP), regulatory requirements, and ethical guidelines.
- Reduction in protocol deviations or violations that compromise study integrity.
- Strengthened regional capacity to conduct high-quality trials without over-reliance on external expertise.
- Enhanced ability to analyze interim data and make informed safety decisions during clinical trials.
- Sustained Capacity for Vaccine Safety Surveillance.
